
June 23 (Reuters) - Merck & Co Inc MRK.N:
MERCK ANNOUNCES PHASE 3 HYPERION STUDY OF WINREVAIR™ (SOTATERCEPT-CSRK) MET PRIMARY ENDPOINT IN RECENTLY DIAGNOSED ADULTS WITH PULMONARY ARTERIAL HYPERTENSION (PAH)
MERCK & CO INC - WINREVAIR REDUCED RISK OF CLINICAL WORSENING EVENTS IN PAH PATIENTS
MERCK & CO INC - HYPERION MET PRIMARY ENDPOINT OF TIME TO CLINICAL WORSENING
MERCK & CO INC - WINREVAIR SAFETY PROFILE CONSISTENT WITH PREVIOUS STUDIES